Anion Exchange Chromatography for Polypeptide Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biopharmaceutical industry faces challenges in purifying therapeutic proteins due to the presence of acidic variants, such as deamidated species, which inhibit the potency of the final drug product, and existing purification methods are complex, costly, and difficult to scale up while maintaining product integrity and purity.
Innovation Solution
A method involving anion exchange chromatography using a quaternary amine or tertiary amine AIEX matrix, where the active polypeptide or immunoconjugate is separated from deamidated variants by eluting with a high salt buffer, effectively removing up to 99% of the acidic or deamidated species, thereby enhancing the purity and potency of the final product.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification schemes are used to remove acidic variants, then purity requirements are met, but the process becomes complex and costly
Solution Approach 1:
The patent combines multiple purification objectives (removing acidic variants, maintaining potency, achieving required purity) into a single integrated anion exchange chromatography step. This merging of functions eliminates the need for multiple separate process steps, thereby reducing overall process complexity while maintaining high purity standards.
Solution Approach 2:
The anion exchange chromatography method serves multiple functions simultaneously: it removes acidic variants, maintains polypeptide potency, and achieves pharmaceutically acceptable purity levels. This multi-functionality in a single step reduces the number of required process operations and simplifies the overall purification scheme.
2Manufacturing precision
If multiple purification steps are implemented to remove deamidated species, then purity is improved, but productivity decreases
Solution Approach 1:
The patent consolidates multiple purification steps into one anion exchange chromatography operation that simultaneously achieves high purity removal of deamidated species (up to 99% removal) while maintaining high throughput. This eliminates the need for sequential purification steps that would reduce overall productivity.
Solution Approach 2:
The method employs specific parameter optimization in anion exchange chromatography, including pH control and salt gradient elution conditions, to achieve both high purity (99% removal of acidic variants) and high productivity in a single step. By adjusting these parameters, the process maximizes both purification efficiency and throughput.
3Productivity
If simple purification methods are used, then productivity is maintained, but purity requirements are not met
Solution Approach 1:
The patent uses anion exchange chromatography with optimized parameters (pH, ionic strength, elution gradient) to achieve both high productivity and high purity (99% removal of acidic variants). By carefully controlling these parameters, the method delivers pharmaceutically acceptable purity levels while maintaining efficient throughput.
Solution Approach 2:
The patent replaces complex multi-step mechanical purification processes with a single chromatography-based separation method. This substitution maintains high productivity while achieving superior purity through the selective binding and elution properties of anion exchange resin, effectively removing deamidated species that simpler methods cannot eliminate.
4Manufacturing precision
If affinity purification is used to achieve high purity, then potency is maintained, but the process becomes difficult to scale
Solution Approach 1:
The anion exchange chromatography method serves as a universal purification approach that can be applied across different polypeptide products and scales. Unlike affinity purification which requires product-specific ligands, this method provides a generalizable platform that maintains potency and achieves high purity while being easily scalable from laboratory to manufacturing scale.
Solution Approach 2:
The method employs scalable parameter adjustments in anion exchange chromatography, where pH and ionic strength conditions can be optimized for different products and scales. This flexibility allows the same basic process to be scaled up for manufacturing while maintaining both high purity (removal of acidic variants) and potency, unlike affinity methods that are more difficult to scale.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach simplifies the purification process, improves throughput, and maintains the integrity and purity of the molecule, ensuring high-quality and safe drug substances by effectively removing deamidated variants and enhancing the bioactivity of the polypeptide or immunoconjugate.
Implementation Method 1
contacting the immunoconjugate with an anion exchange AIEX chromatography matrix
Implementation Method 2
eluting the bound immunoconjugate from the AIEX chromatography matrix with a high salt buffer
Data Source
AI summary
The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.